Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint Expands Capacity for Genotyping Services Offering

This article has been updated to include the product name for Illumina's genotyping platform.

 

NEW YORK, Jan. 31 (GenomeWeb News) - DNAPrint Genomics said today that it has expanded the capacity for its genotyping services offering from 1.3 million genotypes per day to more than 3.9 million genotypes per day.

 

The company has genotyping facilities at headquarters in Sarasota, Fla., as well as at facilities in Richmond, Calif., and Toronto, Canada. The US laboratories use Beckman Coulter's GenomeLab SNPstream genotyping platform, while the Toronto lab uses Illumina's BeadStation.

 

DNAPrint did not provide details on the additional capacity that it has added for these platforms. Company officials could not be reached for comment.

 

The company said that the increase in processing capacity will enable it "to process clinical trials samples to ensure that patient population groups are accurately categorized, and perform large-scale genotyping work for the various industries interested."

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.